| [1] |
张继萍, 任丽娟, 赵亚娟 , 等. 30例耐药结核性脑膜炎脑脊液细胞学动态分析. 皖南医学院学报, 2015,34(6):561-563.
|
| [2] |
杜亚东, 初乃惠, 蔡宝云 , 等. 耐多药结核性脑膜炎4例报道并文献复习. 中国临床医生, 2013,41(3):63-66.
|
| [3] |
杨元利, 张永峰, 刘元 , 等. GeneXpert/TB/RIF技术对成年人结核性脑膜炎诊断价值的研究. 中国防痨杂志, 2017,39(9):980-984.
|
| [4] |
刘锐, 张焕, 陈素丽 , 等. Xpert MTB/RIF在早期诊断结核性脑膜炎中的临床应用价值. 国际检验医学杂志, 2017,38(19):2660-2662.
|
| [5] |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis, 2016 update. Geneva: World Health Organization, 2016.
|
| [6] |
Thwaites GE, Bhavnani SM, Chau TT , et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother, 2011,55(7):3244-3253.
doi: 10.1128/AAC.00064-11
URL
|
| [7] |
Luque S, Grau S, Alvarez-Lerma F , et al. Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. Int J Antimicrob Agents, 2014,44(5):409-415.
doi: 10.1016/j.ijantimicag.2014.07.001
URL
|
| [8] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
|
| [9] |
中华医学会结核病学分会, 利奈唑胺抗结核治疗专家共识编写组. 利奈唑胺抗结核治疗专家共识. 中华结核和呼吸杂志, 2018,41(1):14-19.
|
| [10] |
Agyeman AA, Ofori-Asenso R . Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta analysis. Ann Clin Microbiol Antimicrob, 2016,15(1):41.
doi: 10.1186/s12941-016-0156-y
URL
|
| [11] |
Koh WJ , KanYR,Jeon K ,et al. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: updated analysis of 51 patients. J Antimicrob Chemother, 2012,67(6):1503-1507.
doi: 10.1093/jac/dks078
URL
|
| [12] |
Donald PR . Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb), 2010,90(5):279-292.
doi: 10.1016/j.tube.2010.07.002
URL
|
| [13] |
Akkerman OW, Odish OF, Bolhuis MS , et al. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin Infect Dis, 2016,62(4):523-524.
|
| [14] |
Falzon D, Jaramillo E, Schünemann HJ , et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J, 2011,38(3):516-528.
doi: 10.1183/09031936.00073611
URL
|
| [15] |
Senbayrak S, Ozkutuk N, Erdem H , et al. Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study. Ann Clin Microbiol Antimicrob, 2015,14:47.
doi: 10.1186/s12941-015-0107-z
URL
|
| [16] |
Heemskerk AD, Nguyen MTH, Dang HTM , et al. Clinical outcomes of patients with drug-resistant tuberculous meningitis treated with an intensified antituberculosis regimen. Clin Infect Dis, 2017,65(1):20-28.
doi: 10.1093/cid/cix230
URL
|
| [17] |
Vinnard C, King L, Munsiff S , et al. Long-term mortality of patients with tuberculous meningitis in New York City: a cohort study. Clin Infect Dis, 2017,64(4):401-407.
|
),初乃惠(
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
